Centre places fresh order for 440 million Covaxin, Covishield doses

Additionally, 30 per cent of advance for procurement of both the Covid Vaccines has been released to Serum Institute of India and Bharat Biotech, says govt

Covaxin, Covishield
Centre had already placed an order to purchase 300 million vaccine doses from Biological E, recently | Photo: Bloomberg
BS Web Team New Delhi
2 min read Last Updated : Jun 08 2021 | 5:55 PM IST
A day after Prime Minister Narendra Modi announced a centralised vaccine procurement system, the Government of India, on Tuesday, has placed fresh orders for 440 million jabs.

The government has placed an order with Serum Institute of India (SII) for 250 million doses of Covishield and with Bharat Biotech for 190 million doses of Covaxin.

"With the aim to further universalise the countrywide vaccination drive, all citizens above 18 years of age can receive the coronavirus vaccine doses free of cost at government health facilities," said the union health ministry.

These 440 million doses of vaccines will be available till December 2021, starting now. Additionally, 30 per cent of the advance for procurement of both the Covid Vaccines has been released to Serum Institute and Bharat Biotech.

Centre had already placed an order to purchase 300 million vaccine doses from Biological E, recently, which will be available by September.

Prime Minister Narendra Modi on Monday announced that the Central government will take back control of the vaccine procurement and provide free jabs to the states for inoculation of everyone aged above 18 years.

"Centre will buy 75 per cent of the total vaccine production, including 25 per cent of the state quota."

The Prime Minister said that the Centre had reserved its policy only on the demand of several states. 

Modi said private sector hospitals can continue to procure 25 per cent of vaccines, but their service charge would be capped at Rs 150 per dose over fixed price of the vaccine.

Addressing a press briefing, Dr V K Paul of NITI Aayog said: "We should wait for Biological E to announce the price of their vaccine (Corbevax). It will depend on our negotiation with the company, under the new policy. The financial aid that has been given will meet part of the price."

On vaccine price for hospitals, Paul said that price to private sectors hospitals will be decided by vaccine manufacturers and states will aggregate demand of private sector, which means they will oversee how much network of facilties it has, and how many doses does it require.

One subscription. Two world-class reads.

Already subscribed? Log in

Subscribe to read the full story →
*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

Topics :CoronavirusCoronavirus TestsCoronavirus Vaccine

Next Story